Liver News and Research

RSS

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Two NJIT biomedical researchers have received the prestigious Coulter Foundation Translational Awards for promising patent applications that may some day extend peoples' lives.The Coulter program provides funding for professors in established biomedical engineering departments within the U.S. Initial funding for each professor will be at least $200,000 over a two-year period.

11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Pharmasset third-quarter net loss increases to $16.0 million

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2010.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Vena cava blood clot filters may cause potential life-threatening complications: Study

Two specific types of vena cava filters, devices used to prevent blood clots from reaching the lungs, appear to have evidence of fracturing inside the body, with some fractured fragments traveling to the heart and causing potentially life-threatening complications, according to a report posted online today that will appear in the November 8 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Aug 2010

Increase of alcohol taxes can reduce alcohol-related deaths

Adjusting the alcohol tax in Florida to account for inflation since 1983 would prevent 600 to 800 deaths each year in that state from diseases caused by chronic heavy alcohol use, according to a new study from the University of Florida. The Florida legislature last increased alcohol taxes in 1983.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

9 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

Cancer Research UK scientists have used the immune system coupled with a virus found in horses and cattle, to hunt and purge cancer cells through the lymphatic system, a study reveals in Nature Medicine.Studying mice, the researchers found that the vesicular stomatitis virus (VSV), carried by a type of white blood cell called T cells acted as a 'cancer hunter', tracking down tumour cells in the lymph nodes, liver and spleen, and killed them, leaving normal healthy cells unharmed. At the same time, VSV also helped to trigger an immune response against the tumour, significantly improving the anti-cancer effect.

6 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

German Virtual Liver Network aims to grasp whole organ and functions in computer model

The aim of this unique research consortium is to grasp the whole organ and its functions in a computer model

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

The true power of genomic research lies in its ability to help scientists understand biological processes, particularly those that - when altered - can lead to disease. This power is demonstrated dramatically in a pair of papers published today in the journal Nature. In the first, a global team of researchers describes 95 different variations across the genome that contribute in different degrees to alterations in blood cholesterol and triglyceride levels in multiple human populations. In the second report, close examination of just one of these common variants not only reveals the involvement of an unexpected genetic pathway in lipid metabolism but also provides a blueprint for using genomic findings to unravel biological connections between lipid levels and coronary heart disease.

5 Aug 2010

NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC

Celsion Corporation announced today that the consensus recommendations of the National Cancer Institute (NCI) Clinical Trials Planning Meeting (CTPM) for Hepatocellular Carcinoma have been released and published in the August 2010 issue of Journal of Clinical Oncology, the official publication of American Society of Clinical Oncology (ASCO). In addition to evaluating the current standard of care, the NCI panel also recommended Celsion's Phase III ThermoDox ® HEAT Study as a Priority Clinical Trial for HCC.

4 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

Liver News and Research

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Pharmasset third-quarter net loss increases to $16.0 million

Synta second-quarter net loss increases to $9.1 million

Vena cava blood clot filters may cause potential life-threatening complications: Study

Increase of alcohol taxes can reduce alcohol-related deaths

Isis second-quarter pro forma net operating loss increases to $15.5 million

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Micromet second-quarter 2010 total revenues increase to $6.5 million

German Virtual Liver Network aims to grasp whole organ and functions in computer model

Genzyme, Isis announce results of two mipomersen phase 3 studies

Alnylam second-quarter revenues increase to $26.6 million

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News